*3.5.1 Non-contraceptive uses*

Daily use of progestin protects against the development of endometrial cancer [59]. In addition, NET acetate has demonstrated efficacy in treating dysmenorrhea, abnormal uterine bleeding, and endometriosis-related pain, albeit at higher doses (2.5–15 mg per day) [60]. A single-arm trial of continued DRSP use over 13 cycles in adolescent females reported reduced rates of dysmenorrhea, as well as a corresponding decrease in the use of pain medication to treat the aforementioned dysmenorrhea [61].

Although POPs neither protect from nor increase the risk of acquiring STIs, progestin-induced thickening and increased viscosity of the cervical mucus has been hypothesized to inhibit the ascent of bacteria and thus potentially reduce the risk of PID development. Nevertheless, all women at risk of STI acquisition should be advised to use a condom.
